ACAna Luisa Calich

Ana Luisa Calich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Luisa Calich has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anti‐ribosomal P protein: a novel antibody in autoimmune hepatitis

    by Ana L. Calich, Vilma S. T. Viana, Eduardo Cancado, Francisco Tustumi, Débora R. B. Terrabuio, Elaine P. Leon, Clovis A. Silva, Eduardo F. Borba, Eloisa Bonfa

    Background: Autoantibodies to ribosomal P proteins (anti‐rib P) are specific serological markers for systemic lupus erythematosus (SLE) and are associated with liver involvement in this disease. The similarity in autoimmune background between autoimmune hepatitis (AIH) and SLE‐associated hepatitis raises the possibility that anti‐rib P antibodies might also have relevance in AIH.Aims: To evaluate the frequency and clinical significance of anti‐rib P antibodies in a large AIH cohort.Methods: Sera obtained at diagnosis of 96 AIH patients and of 82 healthy controls were tested for IgG anti‐ribosomal P protein by ELISA. All of the sera were also screened for other lupus‐specific autoantibodies, three patients with the presence of anti‐dsDNA (n = 1) and anti‐Sm (n = 2) were excluded.Results: Moderate to high titres (>40 U) of anti‐rib P antibody were found in 9.7% (9/93) of the AIH patients and none of the controls (P = 0.003). At presentation, AIH patients with and without anti‐rib P antibodies had similar demographic/clinical features, including the frequency of cirrhosis (44.4 vs. 28.5%, P = 0.44), hepatic laboratorial findings (P > 0.05). Importantly, at the final observation (follow‐up period 10.2 ± 4.9 years), the AIH patients with anti‐rib P had a significantly higher frequency of cirrhosis compared with the negative group (100 vs. 60%, P = 0.04).Conclusion: The novel demonstration of anti‐rib P in AIH patients without clinical or laboratory evidence of SLE suggests a common underlying mechanism targeting the liver in these two diseases. In addition, this antibody appears to predict the patients with worse AIH prognoses.


  • Open Access

    Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia

    by Roberta Potenza da Cunha Ribeiro, Hamilton Roschel, Guilherme Gianini Artioli, Thalita Dassouki, Luiz Augusto Perandini, Ana Luisa Calich, Ana Lúcia de Sá Pinto, Fernanda Rodrigues Lima, Eloísa Bonfá, Bruno Gualano

    Introduction: We aimed to gather knowledge on the cardiac autonomic modulation in patients with fibromyalgia (FM) in response to exercise and to investigate whether this population suffers from chronotropic incompetence (CI). Methods: Fourteen women with FM (age: 46 ± 3 years; body mass index (BMI): 26.6 ± 1.4 kg/m2) and 14 gender-, BMI- (25.4 ± 1.3 kg/m2), and age-matched (age: 41 ± 4 years) healthy individuals (CTRL) took part in this cross-sectional study. A treadmill cardiorespiratory test was performed and heart-rate (HR) response during exercise was evaluated by the chronotropic reserve. HR recovery (deltaHRR) was defined as the difference between HR at peak exercise and at both first (deltaHRR1) and second (deltaHRR2) minutes after the exercise test. Results: FM patients presented lower maximal oxygen consumption (VO2 max) when compared with healthy subjects (22 ± 1 versus CTRL: 32 ± 2 mL/kg/minute, respectively; P < 0.001). Additionally, FM patients presented lower chronotropic reserve (72.5 ± 5 versus CTRL: 106.1 ± 6, P < 0.001), deltaHRR1 (24.5 ± 3 versus CTRL: 32.6 ± 2, P = 0.059) and deltaHRR2 (34.3 ± 4 versus CTRL: 50.8 ± 3, P = 0.002) than their healthy peers. The prevalence of CI was 57.1% among patients with FM. Conclusions: Patients with FM who undertook a graded exercise test may present CI and delayed HR recovery, both being indicative of cardiac autonomic impairment and higher risk of cardiovascular events and mortality.


  • Osteoarthritis: can anti-cytokine therapy play a role in treatment?

    by Ana Luisa G. Calich, Diogo S. Domiciano, Ricardo Fuller

    Osteoarthritis (OA) is the most common joint disorder worldwide, and it has an enormous socioeconomic impact both in the United States and throughout the world. The degree of articular inflammation is usually associated with the disease’s progression, indicating that this process could contribute to articular damage. IL-1 beta and anti-TNF alpha are the two major cytokines players in the physiopathology of OA. Hence, we aimed to review the current literature on the effects of IL-1 and TNF-alpha neutralization as a new OA therapy. In vitro and experimental models showed a reduction in cartilage destruction with IL-1 inhibition therapy by IL-1 receptor antagonists (IL-1Ra). Despite this favorable evidence in animal models, studies on the inhibition of IL-1R in humans are still scarce. Although there is clear evidence that TNF-alpha plays a role in the pathophysiology of OA, only a few experimental trials have investigated the efficacy of blocking this pro-inflammatory cytokine in the treatment of OA. So far, the few studies available in humans using anti-TNF-alpha and IL-1 receptor antagonist are not remarkable, suggesting that further investigation and new therapeutic approaches are needed.